Editorial Standards, Archival Continuity & Domain Disclosure

Citation verification: Participating Centers Directory and Consortium Publications Ledger.

1. Historical Domain Continuity & Academic Preservation

Academic publications, university faculty pages (including McGill University, MUHC / CUSM, University of Manitoba, and the COVID-19 Immunity Task Force), and peer-reviewed articles in PLOS ONE, BMJ RMD Open, and the Mediterranean Journal of Rheumatology continue to cite URLs on atacc-ra.com. Rather than leaving those scholarly hyperlinks dead or allowing commercial hijacking, this site preserves every historical route via HTTP 301 mapping and verified archival context.

The restored site is operated independently for medical education and translational cardio-rheumatology reference. It is not an active patient-enrollment registry and does not claim official endorsement from past consortium institutional hosts. Historical investigator names and university departments cited on the observatory reflect verified peer-reviewed co-authorships and archived public institutional directories.

Clinicians and patients visiting through legacy university citations can inspect the original participating institutions across North America, Nordic Europe, Western Europe, and South Africa on the Participating Centers Registry or cross-check primary PubMed identifiers on the Consortium Publications Ledger. Additionally, bilingual French-language hospital citations from Quebec institutions (including MUHC / CUSM) and historical WordPress query parameters are mapped deterministically so external university repositories never suffer broken academic references or silent soft 404 failures.

2. Historical Industry Support & Conflict-of-Interest Archive

In the original 2012-2019 ATACC-RA portal architecture, an archival collaborator acknowledgement existed at /collaborators/lilly/ recognizing unrestricted educational funding support from Eli Lilly and Company during consortium formation. That historical legacy URL redirects cleanly to this transparency section so external citations remain factually contextualized.

The current ATACC-RA Cardio-Rheumatology Observatory receives no pharmaceutical sponsorship, device manufacturer funding, or commercial advertising revenue. Drug class comparisons (including methotrexate, TNF inhibitors, tocilizumab, JAK inhibitors, and glucocorticoids) reflect published peer-reviewed hazard ratios rather than promotional material. Any future bibliographic correction or conflict-of-interest disclosure notice submitted by participating clinical centers is logged openly under this governance record.

Because rheumatoid arthritis therapies frequently evolve following post-marketing safety evaluations, including regulatory label updates for Janus kinase inhibitors and long-term biologic cardiovascular surveillance trials, all medication comparisons distinguish randomized head-to-head trial findings from observational registry associations and encourage clinicians to consult local prescribing information alongside patient-specific cardiovascular profiles.

3. Quantitative Calibration & Evidence Methodology

All interactive educational calculators on this observatory operate purely client-side without storing patient identifiers or transmitting entered clinical variables across networks. Mathematical estimates follow published peer-reviewed cardiovascular epidemiology conventions for rheumatoid arthritis:

• Framingham & SCORE2 Baseline vs. EULAR 1.5x Multiplier: Because general-population equations omit systemic synovial inflammation, the 2015/2016 EULAR Cardiovascular Risk Management Task Force established a 1.5x multiplicative calibration factor for all confirmed RA patients. While QRISK3 incorporates rheumatoid arthritis directly as an indicator variable (typically adding ~1.25x to 1.4x depending on age and sex), clinics outside the UK applying Framingham, ACC/AHA Pooled Cohort Equations, or European SCORE2 require explicit 1.5x upward adjustment to avoid systematic undertreatment.
• Population-Attributable Fraction (30.4% RA Burden): Derived from Crowson et al. (ATACC-RA, 5,638 patients across 13 centers, Annals of the Rheumatic Diseases 2018), multivariable Cox proportional hazards regression showed that traditional risk factors explained 49.0% of incident cardiovascular events while RA-specific characteristics (elevated DAS28 disease activity, seropositivity for RF or ACPA, and extra-articular manifestations) accounted for 30.4% of observed events.
• Glucocorticoid & JAK Inhibitor Hazard Weighting: Educational safety flags reflect oral prednisone exposure thresholds (>=7.5 mg/day associated with ~1.48x MACE hazard across observational cohorts) alongside ORAL Surveillance randomized non-inferiority bounds (HR 1.33 for MACE and increased VTE among patients aged >=50 with >=1 cardiovascular risk factor, especially age >=65 or current/past smoking).
• Subclinical Plaque Reclassification Rules: Both EULAR and ESC prevention guidelines designate asymptomatic carotid plaque (>=1.5 mm focal protrusion or >50% adjacent intima-media thickness) or coronary artery calcium >=100 Agatston units as a high-risk coronary risk equivalent regardless of calculated baseline score.

4. Editorial Standards & Bibliographic Provenance

Every quantitative claim presented across ATACC-RA observatory modules is cross-checked against PubMed-indexed peer-reviewed manuscripts, official European Alliance of Associations for Rheumatology (EULAR) or European Society of Cardiology (ESC) consensus statements, and regulatory safety communications (FDA/EMA). Where older institutional directories from McGill University, McGill University Health Centre (MUHC / CUSM), Brigham and Women's Hospital, University of Manitoba, or Diakonhjemmet Hospital are cited, archival descriptions clearly distinguish preserved historical cohort roles from contemporary educational synthesis.

Automated bots, testing tools, and preview hosts are explicitly excluded from analytics measurement so editorial traffic telemetry reflects authentic academic and clinician visits. External outbound links to commercial or non-registry websites carry strict nofollow attributes, while direct peer-reviewed PubMed, NEJM, and BMJ Open evidence links are curated solely for citation auditability.

5. Editorial Correspondence & Institutional Corrections

University librarians, consortium investigators, or clinicians requesting bibliographic updates, investigator profile corrections, or archival URL adjustments can contact the editorial desk directly at [email protected]. Messages sent to archival consortium addresses at this domain are routed to the editorial archive inbox for timely academic verification.